# US 2024/0002785 A1 · Production of extracellular vesicles in single-cell suspension using chemically-defined cell culture media

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002785 A1
- Document ID: US20240002785A1
- Status: Published application
- Kind: A1
- Application number: 18/172,176
- Filed: 2023-02-21
- Published: 2024-01-04
- Earliest claimed: 2017-09-21
- Assignees: Lonza Sales AG
- Applicants: Lonza Sales AG
- Inventors: Agata A. VILLIGER; Andrew F. GRUBE; Tik Yan CHAN; Scott D. ESTES; Kathryn E. GOLDEN; Konstantin KONSTANTINOV; Douglas E. WILLIAMS
- Web page: https://patentgrep.com/patent/US20240002785A1

## CPC

- C12N 5/0043: {Medium free of human- or animal-derived components}
- C12P 1/00: Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12N 2500/92: Medium free of human- or animal-derived components
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

Described herein are methods for the production of extracellular vesicles comprising culturing a population of producer cells in single-cell suspension, wherein the cells are cultured in chemically-defined culture medium, wherein the culture medium lacks animal-derived serum and animal-derived components; and obtaining from the cell culture an extracellular vesicle preparation comprising extracellular vesicles. In certain embodiments, the methods comprise perfusion culturing methods, including single-cell perfusion culturing methods and batch-refeed culturing methods. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.

## Claims

### Claim 1

A method of producing extracellular vesicles, comprising:
culturing a population of producer cells in single-cell suspension, wherein the cells are cultured in chemically-defined culture medium, wherein the culture medium lacks animal-derived serum and animal-derived components; and
obtaining from the cell culture an extracellular vesicle preparation comprising extracellular vesicles.

### Claim 2 (depends on 1)

The method of claim 1, wherein the culturing is performed using a perfusion culturing method.

### Claim 3 (depends on 2)

The method of claim 2, wherein the perfusion culturing method is tangential flow filtration perfusion or alternating tangential flow filtration perfusion.

### Claim 4 (depends on 2)

The method of claim 2, wherein the method results in increased cell viability compared to cells cultured using a fed-batch culturing method cultured for the same number of days.

### Claim 5 (depends on 2)

The method of claim 2, wherein the extracellular vesicle preparation comprises reduced proteinaceous contaminants, nucleic acid contaminants, small molecules, metabolites, membranous contaminants, or combinations thereof, compared to extracellular vesicle preparations harvested using a fed-batch culturing method cultured for the same number of days.

### Claim 6 (depends on 2)

The method of claim 2, wherein the extracellular vesicle preparation comprises increased abundance of extracellular vesicles, compared to extracellular vesicle preparations harvested using a fed-batch culturing method cultured for the same number of days.

### Claim 7 (depends on 2)

The method of claim 2, wherein the cells are cultured in a bioreactor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the bioreactor is a perfusion bioreactor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the bioreactor is connected to a cell retention device.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cells are mammalian cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cells are human cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein the human cells are human kidney cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cells are HEK293 cells.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cells are HEK293 SF cells.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cells overexpress an exosome specific protein, thereby generating engineered extracellular vesicles overexpressing the exosome specific protein.

### Claim 16 (depends on 15)

The method of claim 15, wherein the exosome-specific protein is PTGFRN, BSG, IGSF2, IGSF3, IGSF8, ITGB1, ITGA4, SLC3A2, or ATP transporter, or a fragment or variant thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the exosome-specific protein is PTGFRN or a fragment or variant thereof.

### Claim 18 (depends on 15)

The method of claim 15, wherein the exosome-specific protein is MARCKS, MARCKSL1, or BASP1, or a fragment or variant thereof.

### Claim 19 (depends on 1)

The method of claim 1, wherein the extracellular vesicles comprise at least one therapeutic agent.

### Claim 20 (depends on 1)

The method of claim 1, wherein the extracellular vesicles are exosomes.
